XML 58 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 1 Months Ended 12 Months Ended
Mar. 25, 2025
USD ($)
Sep. 30, 2024
USD ($)
Mar. 31, 2025
USD ($)
Segment
shares
Mar. 31, 2024
USD ($)
Segment
shares
Mar. 31, 2023
USD ($)
Feb. 19, 2025
USD ($)
Dec. 31, 2024
USD ($)
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Cash and cash equivalents     $ 11,312,000 $ 2,901,000      
Restricted cash     143,000 143,000      
Accumulated deficit     (342,157,000) (339,669,000)      
Cash flow from operations     9,461,000 14,653,000      
Total current assets     12,131,000 3,936,000      
Total current liabilities     3,737,000 $ 1,860,000      
Working capital     $ 8,400,000        
Issuance of common stock | shares     1,898,068 839,814      
Stockholders' equity     $ 10,492,000 $ 3,601,000     $ 364,000
Reverse stock split, description     1-for-12        
Reverse stock split, conversion ratio     0.0833        
Proceeds from issuance of common stock, net     $ 8,847,000 1,437,000      
Insurance premium financing agreement description     In September 2024, the Company entered into an insurance premium financing agreement for $0.4 million, with a term of nine months and an annual interest rate of 8.57%. The Company made a down payment of 10% and is required to make monthly principal and interest payments of $44,281 over the term of the agreement, which matures in June 2025. The insurance premium financing liability was approximately $0.1 million as of March 31, 2025. Related prepaid insurance at March        
Financing agreement amount   $ 400,000          
Percentage of down payment   10.00%          
Insurance premium financing liability     $ 128,000        
Prepaid insurance     417,000 445,000      
Restricted cash     $ 100,000 100,000      
Estimated useful life of the fixed assets     The estimated useful lives of the fixed assets range between one and seven years        
Impairment of long-lived assets     $ 0 0      
Escrow receivable     1,000,000        
Period of escrow 15 months            
Dilutive effect     $ 0 $ 0      
Common stock equivalents excluded from computing diluted net loss per share | shares     700,000        
Operating segment | Segment     1 2      
Mosaic Segment [Member]              
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Inventory finished goods     $ 0 $ 300,000      
Insurance Premium Financing Liability [Member]              
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Annual interest rate   8.57%          
Monthly principal and interest payments   $ 44,281          
Prepaid insurance     $ 200,000        
Maximum [Member]              
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Useful life of fixed assets, range     7 years        
Minimum [Member]              
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Percentage of Drug Candidate     10.00%        
Stockholders' equity           $ 2,500,000  
Useful life of fixed assets, range     1 year        
Common stock equivalents excluded from computing diluted net loss per share | shares       100,000      
At The Market Facility [Member]              
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Issuance of common stock | shares     493,372        
Issuance of common stock | shares     493,372        
Proceeds from issuance of common stock, net     $ 4,900,000        
Metacrine's FXR Program [Member] | Maximum [Member]              
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Future milestone     50,000,000        
Potential milestone payments     $ 50,000,000        
Metacrine's FXR Program [Member] | Metacrine, Inc. [Member]              
Description Of Business And Summary Of Significant Accounting Policies [Line Items]              
Consideration of cash payments         $ 4,000,000    
Upfront payment $ 10,000,000       $ 2,000,000    
Closing upfront payment 9,000,000            
Acquired in-process research and development       $ 2,000,000      
Escrow receivable $ 1,000,000